 09 PM / in 12 minutes BRIEF-Merck’s Keytruda Approved In Japan For Use In The Treatment Of Patients With Urothelial Carcinoma Reuters Staff 1 Min Read 
Jan 2 (Reuters) - Merck & Co Inc: 
* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) APPROVED IN JAPAN FOR USE IN THE TREATMENT OF PATIENTS WITH UROTHELIAL CARCINOMA THAT IS UNRESECTABLE WITH RADICAL SURGERY WHO HAVE PROGRESSED FOLLOWING CANCER CHEMOTHERAPY 
* MERCK & CO INC - WILL MARKET KEYTRUDA IN JAPAN AND WILL PROMOTE IT WITH TAIHO PHARMACEUTICAL CO LTD 
* MERCK & CO INC - WITH THE APPROVAL, KEYTRUDA IS NOW INDICATED FOR USE IN FOUR TYPES OF CANCER IN JAPAN  